Despite substantial epidemiologic evidence supports the association between cardiometabolic biomarkers and risk of cardiovascular, metabolic disease and cancer, how these biomarkers may influence all-cause and cause-specific mortality remain to be established. Previous studies were limited by the relatively small sample size, inclusion of men or women only, short duration of follow up, examination of CVD or cancer mortality only, or inadequate control for confounding. Therefore, a systematic investigation of cardiometabolic biomarkers with mortality in a large-scale cohort is needed to better understand the role of metabolic disturbances in death risk. We will utilize data from UK biobank to prospectively investigate associations of 14 serum biomarkers, including lipid profiles (i.e., Cholesterol, Direct Low Density Lipoprotein, HDL-Cholesterol, Triglyceride, Apolipoprotein A, and Lipoprotein (a)), inflammatory marker (C-reactive Protein), IGF1, HbA1c, glucose, and sex hormones (i.e., testosterone, oestradiol, sex hormone binding globulin), with the risk of all-cause and cause-specific mortality (i.e., death from CVD, cancer, and other causes).
|Return ID||App ID||Description||Archive Date|
|3736||52217||Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank||6 Aug 2021|
|3735||52217||Vitamin D Status and Risk of All-Cause and Cause-Specific Mortality in a Large Cohort: Results From the UK Biobank||6 Aug 2021|
|3737||Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank||Fan et al||2021||European Journal of Epidemiology (2021)|
|3736||Vitamin D Status and Risk of All-Cause and Cause-Specific Mortality in a Large Cohort: Results From the UK Biobank||Fan et al||2014||The Journal of Clinical Endocrinology and Metabolism (2020)|